NL-OMON55633
Not yet recruiting
Not Applicable
Predicting Outcome and Disease Course in acquired demyelinating syndromes in childhood - PROUD-kids 2.0
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Multiple Sclerosis
- Sponsor
- Erasmus MC, Universitair Medisch Centrum Rotterdam
- Enrollment
- 1200
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Age under 18 years
- •2\. Auto\-immune mediated, demyelinating disorder of the CNS
- •3\. No other suspected disease causing demyelination in the CNS
- •4\. Written informed consent is obtained of parents or caregivers. In case the
- •patient is 12 years of age or older, the patient needs to provide written
- •informed consent as well. , Healthy controls
- •1\. Age under 18 years
- •2\. No known systemic auto\-immune disease
- •3\. Full siblings (same father and same mother) of the patient are eligible and
- •not blood\-related children sharing similar environments (school, neighbourhood
Exclusion Criteria
- •1\) Age of onset above 18 years
- •2\) Inflammation in the CNS by other causes than ADS (for example systemic lupus
- •erythematosus, Sj\*gren syndrome, sarcoidosis,).
- •3\) If written informed consent is not obtained.
- •4\) Withdrawal from study by patient and/or parents.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Prediction of illness course and outcome in patients with a first episode of psychosisNL-OMON47512niversitair Medisch Centrum Utrecht86
Completed
Not Applicable
Clinical Outcomes and Prognostic Factors to Predict Treatment Response in High Risk Neuroblastoma Patients Receiving Topotecan and Cyclophosphamide Containing Induction Regimen: A Prospective Multicenter StudyThe study is an observational study and aims to evaluate the clinical outcomes and classify relevant prognostic factors to measure induction response among high risk neuroblastoma patients in Thailandhigh risked neuroblastoma,topotecan,induction therapy,treatment response,prognostic factor,treatment-related toxicityTCTR20190602002Phramongkutklao Hospital and College of Medicine107
Recruiting
Phase 3
Determining factors of prognosis and morbidity in Chronic Chagas Heart Disease - phase IIIRBR-9gm9bzniversidade Federal de Minas Gerais
Recruiting
Not Applicable
The prognosis investigation of the patients with acute heart failure- by using various indicatorsacute heart failureJPRN-UMIN000015246Osaka General Medical Center500
Recruiting
Not Applicable
A prospective view on disease course and associated biomarkers in Hereditary Cerebral Hemorrhage With Amyloidosis Dutch type (HCHWA-D)HCHWA-Dhereditary cerebral amyloid angiopathyHereditary Cerebral Hemorrhage With Amyloidosis Dutch type10007963NL-OMON55383eids Universitair Medisch Centrum150